112 related articles for article (PubMed ID: 8958942)
1. The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma.
Rook AH; Kubin M; Fox FE; Niu Z; Cassin M; Vowels BR; Gottleib SL; Vonderheid EC; Lessin SR; Trinchieri G
Ann N Y Acad Sci; 1996 Oct; 795():310-8. PubMed ID: 8958942
[TBL] [Abstract][Full Text] [Related]
2. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome.
Rook AH; Kubin M; Cassin M; Vonderheid EC; Vowels BR; Wolfe JT; Wolf SF; Singh A; Trinchieri G; Lessin SR
J Immunol; 1995 Feb; 154(3):1491-8. PubMed ID: 7822812
[TBL] [Abstract][Full Text] [Related]
3. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells.
Vowels BR; Cassin M; Vonderheid EC; Rook AH
J Invest Dermatol; 1992 Jul; 99(1):90-4. PubMed ID: 1607682
[TBL] [Abstract][Full Text] [Related]
4. Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sézary syndrome: its enhancement by interferon-gamma (IFN-gamma) and IL-12 and fluctuations in association with disease activity.
Seo N; Tokura Y; Matsumoto K; Furukawa F; Takigawa M
Clin Exp Immunol; 1998 Jun; 112(3):403-9. PubMed ID: 9649208
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis.
Rook AH; Gottlieb SL; Wolfe JT; Vowels BR; Sood SS; Niu Z; Lessin SR; Fox FE
Clin Exp Immunol; 1997 Jan; 107 Suppl 1():16-20. PubMed ID: 9020930
[TBL] [Abstract][Full Text] [Related]
6. Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sézary syndrome: circumvention by hexameric soluble CD40L.
French LE; Huard B; Wysocka M; Shane R; Contassot E; Arrighi JF; Piguet V; Calderara S; Rook AH
Blood; 2005 Jan; 105(1):219-25. PubMed ID: 15315967
[TBL] [Abstract][Full Text] [Related]
7. Sézary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines.
Wysocka M; Zaki MH; French LE; Chehimi J; Shapiro M; Everetts SE; McGinnis KS; Montaner L; Rook AH
Blood; 2002 Nov; 100(9):3287-94. PubMed ID: 12384429
[TBL] [Abstract][Full Text] [Related]
8. Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells.
Fox FE; Kubin M; Cassin M; Niu Z; Trinchieri G; Cooper KD; Rook AH
J Interferon Cytokine Res; 1999 Apr; 19(4):407-15. PubMed ID: 10334392
[TBL] [Abstract][Full Text] [Related]
9. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
Yoo EK; Cassin M; Lessin SR; Rook AH
J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
[TBL] [Abstract][Full Text] [Related]
10. Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma.
Zaki MH; Wysocka M; Everetts SE; Wang KS; French LE; Ritz J; Rook AH
J Invest Dermatol; 2002 Feb; 118(2):366-71. PubMed ID: 11841558
[TBL] [Abstract][Full Text] [Related]
11. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12.
Skeiky YA; Guderian JA; Benson DR; Bacelar O; Carvalho EM; Kubin M; Badaro R; Trinchieri G; Reed SG
J Exp Med; 1995 Apr; 181(4):1527-37. PubMed ID: 7699334
[TBL] [Abstract][Full Text] [Related]
12. Abnormal cytokine expression in Sézary and adult T-cell leukemia cells correlates with the functional diversity between these T-cell malignancies.
Tendler CL; Burton JD; Jaffe J; Danielpour D; Charley M; McCoy JP; Pittelkow MR; Waldmann TA
Cancer Res; 1994 Aug; 54(16):4430-5. PubMed ID: 7913876
[TBL] [Abstract][Full Text] [Related]
13. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection.
O'Sullivan ST; Lederer JA; Horgan AF; Chin DH; Mannick JA; Rodrick ML
Ann Surg; 1995 Oct; 222(4):482-90; discussion 490-2. PubMed ID: 7574928
[TBL] [Abstract][Full Text] [Related]
14. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma.
Vowels BR; Lessin SR; Cassin M; Jaworsky C; Benoit B; Wolfe JT; Rook AH
J Invest Dermatol; 1994 Nov; 103(5):669-73. PubMed ID: 7963654
[TBL] [Abstract][Full Text] [Related]
15. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.
Zhang Q; Nowak I; Vonderheid EC; Rook AH; Kadin ME; Nowell PC; Shaw LM; Wasik MA
Proc Natl Acad Sci U S A; 1996 Aug; 93(17):9148-53. PubMed ID: 8799169
[TBL] [Abstract][Full Text] [Related]
16. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12.
Wysocka M; Newton S; Benoit BM; Introcaso C; Hancock AS; Chehimi J; Richardson SK; Gelfand JM; Montaner LJ; Rook AH
Clin Lymphoma Myeloma; 2007 Sep; 7(8):524-34. PubMed ID: 18021470
[TBL] [Abstract][Full Text] [Related]
17. Increased interleukin 5 production in eosinophilic Sézary syndrome: regulation by interferon alfa and interleukin 12.
Suchin KR; Cassin M; Gottleib SL; Sood S; Cucchiara AJ; Vonderheid EC; Rook AH
J Am Acad Dermatol; 2001 Jan; 44(1):28-32. PubMed ID: 11148473
[TBL] [Abstract][Full Text] [Related]
18. [Cutaneous lymphoma of the Sézary and Bouvrain type. Progress in physiopathologic and therapeutic outlook].
Bagot M
Bull Acad Natl Med; 1998; 182(5):927-37; discussion 937-8. PubMed ID: 9735499
[TBL] [Abstract][Full Text] [Related]
19. Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication.
Dummer R; Döbbeling U; Geertsen R; Willers J; Burg G; Pavlovic J
Blood; 2001 Jan; 97(2):523-7. PubMed ID: 11154232
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
